Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback